Cutaneous candidiasis caused by Candida glabrata in a HIV/AIDS patient. 2013

Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
Department of Infectious Diseases, Erciyes University, Kayseri, Turkey.

Cutaneous Candida infections may occur in patients with HIV/AIDS, cancer, receiving chemotherapy and solid organ transplantation. A 32-year-old woman was admitted to the department suffering from pruritic and erythematous plaque on left side of her face for the past two months. The patient was HIV positive, diagnosed five years previously, and had been on antiretroviral therapy (tenofovir/emtricitabine and lopinavir/ritonavir) for a year. She was not compliant with the medication. Elevated HIV RNA load and decreased CD4+ lymphocyte count were observed. Fungal elements were detected from the skin scraping sample taken from the facial plaque. Fluconazole-sensitive Candida glabrata was isolated from this sample. Topical clotrimazole ointment and systemic fluconazole 400 mg/day were used. After systemic fluconazole therapy was continued for two months, the plaque was cured. C. glabrata rarely causes cutaneous infection without involving the mucous membranes. Presentation of cutaneous fungal infections in HIV patients with decreased CD4+ T lymphocyte counts can be atypical and require extensive antifungal treatment.

UI MeSH Term Description Entries
D002179 Candidiasis, Cutaneous Candidiasis of the skin manifested as eczema-like lesions of the interdigital spaces, perleche, or chronic paronychia. (Dorland, 27th ed) Moniliasis, Cutaneous
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015725 Fluconazole Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. Apo-Fluconazole,Béagyne,Diflucan,Fluc Hexal,FlucoLich,Flucobeta,Fluconazol AL,Fluconazol AbZ,Fluconazol Stada,Fluconazol von ct,Fluconazol-Isis,Fluconazol-ratiopharm,Flunazul,Fungata,Lavisa,Loitin,Neofomiral,Oxifungol,Solacap,Triflucan,UK-49858,Zonal,Apo Fluconazole,Fluconazol Isis,Fluconazol ratiopharm,UK 49858,UK49858
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents

Related Publications

Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
October 1994, Annales de gastroenterologie et d'hepatologie,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
January 2021, The Pan African medical journal,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
October 1994, Journal of comparative pathology,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
January 1992, Annales de dermatologie et de venereologie,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
June 2002, The Veterinary record,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
June 2001, Japanese journal of infectious diseases,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
January 2018, International journal of immunopathology and pharmacology,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
September 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
July 2022, Journal of dental sciences,
Hayati Demiraslan, and Selma Alabay, and Aysegul Ulu Kilic, and Murat Borlu, and Mehmet Doganay
November 2001, American journal of ophthalmology,
Copied contents to your clipboard!